354.F Collegium Pharmaceutical Inc
- Market cap
- EUR 684M
- P/E
- 24.2x
- P/B
- 2.52x
- ROE
- 9.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 354.F undervalued?
Graham number354.F trades 64.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Collegium Pharmaceutical Inc fundamental analysis
No fundamental analysis for Collegium Pharmaceutical Inc yet.
Collegium Pharmaceutical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtam…
Full company profileCollegium Pharmaceutical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Collegium Pharmaceutical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.71M | 28.5M | 280M | 297M | 310M | 277M | 464M | 567M | 631M | 781M | 813M |
| Gross Profit | 1.50M | 25.9M | 115M | 103M | 180M | 151M | 209M | 326M | 377M | 463M | 471M |
| Operating Income | -94.1M | -75.4M | -20.7M | -23.7M | 56.2M | 22.2M | 33.3M | 167M | 167M | 178M | 80.6M |
| EBITDA | - | -74.9M | 91.9M | -6.33M | 118M | 17.6M | 34.4M | 308M | 342M | 401M | 329M |
| Net Income | -94.2M | -74.9M | -39.1M | -22.7M | 26.8M | 71.5M | -25.0M | 48.2M | 69.2M | 62.9M | 28.3M |
| EPS | - | -2.28 | -1.18 | -0.67 | 0.77 | 2.12 | -0.74 | 1.51 | 2.20 | 1.98 | 0.87 |
| Balance Sheet | |||||||||||
| Total Assets | 162M | 136M | 291M | 306M | 644M | 692M | 1.17B | 1.14B | 1.66B | 1.66B | 2.10B |
| Total Liabilities | 27.1M | 31.5M | 200M | 219M | 458M | 489M | 979M | 948M | 1.43B | 1.36B | 1.80B |
| Shareholders' Equity | 135M | 104M | 91.6M | 87.4M | 186M | 203M | 195M | 195M | 229M | 302M | 296M |
| Cash & Short-term Investments | 153M | 119M | 147M | 170M | 174M | 186M | 174M | 239M | 70.6M | 231M | 145M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -75.1M | -67.0M | 169M | 27.8M | 93.9M | 104M | 124M | 268M | 205M | 329M | 287M |
| Capital Expenditure | 2.98M | 990K | 5.48M | 6.44M | 5.55M | 1.94M | 1.62M | 1.24M | 1.65M | 1.74M | 1.39M |
| Free Cash Flow | - | -68.0M | 145M | 21.3M | -280M | 102M | 123M | 266M | 203M | 328M | 285M |
| Ratios | |||||||||||
| ROE | -69.8% | -71.9% | -42.7% | -26.0% | 14.4% | 35.2% | -12.8% | 24.6% | 30.2% | 20.8% | 9.5% |
| ROA | -58.1% | -55.2% | -13.4% | -7.4% | 4.2% | 10.3% | -2.1% | 4.2% | 4.2% | 3.8% | 1.3% |
| Net Profit Margin | -5,504.1% | -262.9% | -14.0% | -7.7% | 8.6% | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% | 3.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Collegium Pharmaceutical Inc dividends
Collegium Pharmaceutical Inc has not paid dividends in the last 9 fiscal years.
Who owns Collegium Pharmaceutical Inc
- Insiders 1.21%
- Institutions 98.80%
- Public & others 0.00%
- Shares outstanding 31.1M
- Free float 28.3M
Collegium Pharmaceutical Inc company profile
- Company name
- Collegium Pharmaceutical Inc
- Ticker
- 354.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 423
- Fiscal year end
- December
- Address
- 100 Technology Center Drive, Stoughton, MA, United States, 02072
- Phone
- 781 713 3699
- Website
- collegiumpharma.com
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical Inc management
9- Mr. Vikram KarnaniCEO, President & Director · born 1975
- Ms. Colleen TupperExecutive VP & CFO · born 1976
- Mr. David DieterExecutive VP, General Counsel & Corporate Secretary · born 1964
- Dr. Thomas B. Smith FAAFP, M.D.Executive VP & Chief Medical Officer · born 1961
- Mr. Ian Karp M.B.A.Head of Investor Relations
- Ms. Jessica CotroneSenior Vice President of Corporate Communications & Corporate Affairs
- Ms. Jane GonnermanExecutive Vice President of Strategy & Corporate Development
- Mr. Dean J. PatrasChief People Officer
- Mr. Scott SudduthEVP & Head of Technical Operations